Millenia Hope Inc.
Millenia Hope acquires pending patent describing compounds that inhibit HIV-1 RNase_H
Published in AIDS Weekly and Law, March 30th, 2006
The viral RNase_H has been shown to be essential for HIV replication. There are no inhibitors of HIV-1 RNase_H in clinical development at this time. In fact, very few such inhibitors have even been identified for this target. Successful development of this drug will play an important role in the treatment of AIDS patients who have become resistant to current therapy. Projected revenue for an orally bioavailable (first in class) drug for AIDS is estimated at $350-$500 million U.S.
The current market of AIDS drugs is $6...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly and Law
Source: AIDS Weekly and Law (2006-03-30)
More Articles from AIDS Weekly and Law
- CytoDyn, Inc.
CytoDyn gets green light for China joint venture - Fiocruz MS, Rio de Janeiro
Advanced HIV cases suggest large pool of undiagnosed HIV infections in Southeast Brazil - Jewish General Hospital, Montreal
Data advance knowledge in HIV/AIDS pathogenesis research - U.S. National Institutes of Health
Cancer risk increased among HIV-infected persons in Uganda - Albert Einstein College of Medicine, Bronx
HIV knowledge lower among sexually inexperienced youth - Community Education Group
First national women and girls HIV/AIDS Awareness Day - More from this issue of AIDS Weekly and Law
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
